Release Inspections USP 797
Sterile Non-Hazardous Compounding <797>
Release Inspections
Sterile Non-Hazardous Compounding <797>
Purpose/ Applicability: To outline the proper procedure for the release inspections associated with sterile non-hazardous compounded products.
Scope: This applies to all CSPs that are batched.
Definition(s):
CSP: Compounded Sterile Product
USP: United States Pharmacopeia
Equipment: N/A
Procedure:
- Products should be stored in accordance with specific storage requirements identified for that preparation
- Master formulation / Compounding record
- Note: If product should be protected from light, must be stored in light protect bag
- CSPs are allowed to be dispensed / stocked prior to receiving completed sterility testing once initial testing has been completed for 3 batches
- If something grows from sterility testing, then a new batch should be made ASAP; New batch can be put back into inventory unless we have multiple batches in a row with growth
- At this point in time the sterility of the cleanroom and our procedures need to be assessed
- If something grows from sterility testing, then a new batch should be made ASAP; New batch can be put back into inventory unless we have multiple batches in a row with growth
- Follow specifications of USP <71> to determine appropriate amount of CSPs to remove per batch for sterility testing
- 10% of batch
- Once sterility has been ascertained for product for 3 consecutive batches, can pull one CSP per batch based on medication dispensary policy
- Product is logged on appropriate form, diagnostic lab is contacted, and CSP is taken to diagnostic lab for sterility testing
- Pharmacist(s) review initial and final reports and log them within excel chart here: pharmacy drive à pharmacy docs à vials submitted for microbial testing
- Follow procedure outline in SOP: Sterility Testing (if more information is needed)
- If initial product report comes back with growth, CSP must be pulled immediately
- Wait for final product report to confirm prior to disposing of product
- If final product report comes back with growth, CSP must be pulled immediately (if not already) and disposed of properly
References:
- US Pharmacopeial Convention, Inc. United States Pharmacopeia 26-National Formulary 21. Council of Experts Committee on Parenteral Products: Compounding and Preparation. Chapter <797> Pharmaceutical Compounding—Sterile Preparations. PF 2003; 29(3): 750–809.
- Buchanan EC, McKinnon BT, Scheckelhoff DJ et al. Principles of Sterile Product Preparations. 1st ed. Bethesda, MD: American Society of Health-System Pharmacists; 2002.